240 related articles for article (PubMed ID: 22370160)
1. Pharmacokinetic-directed high-dose busulfan combined with cyclophosphamide and etoposide results in predictable drug levels and durable long-term survival in lymphoma patients undergoing autologous stem cell transplantation.
Zhang H; Graiser M; Hutcherson DA; Dada MO; McMillan S; Ali Z; Flowers CR; Waller EK
Biol Blood Marrow Transplant; 2012 Aug; 18(8):1287-94. PubMed ID: 22370160
[TBL] [Abstract][Full Text] [Related]
2. Superior survival after replacing oral with intravenous busulfan in autologous stem cell transplantation for non-Hodgkin lymphoma with busulfan, cyclophosphamide and etoposide.
Dean RM; Pohlman B; Sweetenham JW; Sobecks RM; Kalaycio ME; Smith SD; Copelan EA; Andresen S; Rybicki LA; Curtis J; Bolwell BJ
Br J Haematol; 2010 Jan; 148(2):226-34. PubMed ID: 19821828
[TBL] [Abstract][Full Text] [Related]
3. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma.
Hänel M; Kröger N; Sonnenberg S; Bornhäuser M; Krüger W; Kroschinsky F; Hänel A; Metzner B; Birkmann J; Schmid B; Hoffknecht MM; Fiedler F; Ehninger G; Zander AR
Ann Hematol; 2002 Feb; 81(2):96-102. PubMed ID: 11907790
[TBL] [Abstract][Full Text] [Related]
4. Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies.
Williams CB; Day SD; Reed MD; Copelan EA; Bechtel T; Leather HL; Wingard JR; Abbott BL; Abhyankar S; McGuirk JP
Biol Blood Marrow Transplant; 2004 Sep; 10(9):614-23. PubMed ID: 15319773
[TBL] [Abstract][Full Text] [Related]
5. Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen.
Aggarwal C; Gupta S; Vaughan WP; Saylors GB; Salzman DE; Katz RO; Nance AG; Tilden AB; Carabasi MH
Biol Blood Marrow Transplant; 2006 Jul; 12(7):770-7. PubMed ID: 16785066
[TBL] [Abstract][Full Text] [Related]
6. Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies.
Tran HT; Madden T; Petropoulos D; Worth LL; Felix EA; Sprigg-Saenz HA; Choroszy M; Danielson M; Przepiorka D; Chan KW
Bone Marrow Transplant; 2000 Sep; 26(5):463-70. PubMed ID: 11019834
[TBL] [Abstract][Full Text] [Related]
7. Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma.
Cote GM; Hochberg EP; Muzikansky A; Hochberg FH; Drappatz J; McAfee SL; Batchelor TT; LaCasce AS; Fisher DC; Abramson JS; Armand P; Chen YB
Biol Blood Marrow Transplant; 2012 Jan; 18(1):76-83. PubMed ID: 21749848
[TBL] [Abstract][Full Text] [Related]
8. Daily Weight-Based Busulfan with Cyclophosphamide and Etoposide Produces Comparable Outcomes to Four-Times-Daily Busulfan Dosing for Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
Hill BT; Rybicki L; Carlstrom KD; Jagadeesh D; Gerds A; Hamilton B; Liu H; Dean R; Sobecks R; Pohlman B; Andresen S; Kalaycio M; Bolwell BJ; Majhail NS
Biol Blood Marrow Transplant; 2016 Sep; 22(9):1588-1595. PubMed ID: 27343718
[TBL] [Abstract][Full Text] [Related]
9. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
Kröger N; Zabelina T; Sonnenberg S; Krüger W; Renges H; Stute N; Finkenstein F; Mayer U; Holstein K; Fiedler W; Colberg H; Sonnen R; Kuse R; Braumann D; Metzner B; del Valle F; Erttmann R; Kabisch H; Zander AR
Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
[TBL] [Abstract][Full Text] [Related]
10. High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen.
Geddes M; Kangarloo SB; Naveed F; Quinlan D; Chaudhry MA; Stewart D; Savoie ML; Bahlis NJ; Brown C; Storek J; Andersson BS; Russell JA
Biol Blood Marrow Transplant; 2008 Feb; 14(2):220-8. PubMed ID: 18215782
[TBL] [Abstract][Full Text] [Related]
11. A Comprehensive Assessment of Toxicities in Patients with Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using Thiotepa, Busulfan, and Cyclophosphamide Conditioning.
Scordo M; Bhatt V; Hsu M; Omuro AM; Matasar MJ; DeAngelis LM; Dahi PB; Moskowitz CH; Giralt SA; Sauter CS
Biol Blood Marrow Transplant; 2017 Jan; 23(1):38-43. PubMed ID: 27713090
[TBL] [Abstract][Full Text] [Related]
12. Multicenter study of intravenous busulfan, cyclophosphamide, and etoposide (i.v. Bu/Cy/E) as conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin's lymphoma.
Kim JG; Sohn SK; Chae YS; Yang DH; Lee JJ; Kim HJ; Shin HJ; Jung JS; Kim WS; Kim DH; Suh C; Kim SJ; Eom HS; Bae SH
Bone Marrow Transplant; 2007 Nov; 40(10):919-24. PubMed ID: 17846602
[TBL] [Abstract][Full Text] [Related]
13. A phase I dose-escalation study of etoposide continuous infusion added to busulphan/cyclophosphamide as conditioning prior to autologous or allogeneic stem cell transplantation.
Ritchie DS; Szer J; Roberts AW; Shuttleworth P; Grigg AP
Bone Marrow Transplant; 2002 Nov; 30(10):645-50. PubMed ID: 12420202
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or daily schedule to patients with advanced hematologic malignant disease undergoing stem cell transplantation.
Fernandez HF; Tran HT; Albrecht F; Lennon S; Caldera H; Goodman MS
Biol Blood Marrow Transplant; 2002; 8(9):486-92. PubMed ID: 12374453
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantation.
Tran H; Petropoulos D; Worth L; Mullen CA; Madden T; Andersson B; Choroszy M; Nguyen J; Webb SK; Chan KW
Biol Blood Marrow Transplant; 2004 Nov; 10(11):805-12. PubMed ID: 15505611
[TBL] [Abstract][Full Text] [Related]
16. Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen.
Smith SD; Bolwell BJ; Rybicki LA; Brown S; Dean R; Kalaycio M; Sobecks R; Andresen S; Hsi ED; Pohlman B; Sweetenham JW
Bone Marrow Transplant; 2007 Aug; 40(3):239-43. PubMed ID: 17530000
[TBL] [Abstract][Full Text] [Related]
17. Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study.
Nguyen L; Leger F; Lennon S; Puozzo C
Cancer Chemother Pharmacol; 2006 Jan; 57(2):191-8. PubMed ID: 16133536
[TBL] [Abstract][Full Text] [Related]
18. Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience.
Ulrickson M; Aldridge J; Kim HT; Hochberg EP; Hammerman P; Dube C; Attar E; Ballen KK; Dey BR; McAfee SL; Spitzer TR; Chen YB
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1447-54. PubMed ID: 19822305
[TBL] [Abstract][Full Text] [Related]
19. Autologous stem cell transplantation with busulfan, cyclophosphamide, and etoposide as an intensifying frontline treatment in patients with peripheral T cell lymphomas: a multicenter retrospective trial.
Ahn JS; Yang DH; Jung SH; Chae YS; Sohn SK; Yhim HY; Kwak JY; Lee SR; Kim YK; Kim HJ; Lee JJ
Ann Hematol; 2013 Jun; 92(6):789-97. PubMed ID: 23358616
[TBL] [Abstract][Full Text] [Related]
20. Development and validation of a test dose strategy for once-daily i.v. busulfan: importance of fixed infusion rate dosing.
Kangarloo SB; Naveed F; Ng ES; Chaudhry MA; Wu J; Bahlis NJ; Brown CB; Daly A; Duggan P; Geddes M; Quinlan D; Savoie ML; Shafey M; Stewart DA; Storek J; Yang M; Zacarias N; Yue P; Magliocco AM; Russell JA
Biol Blood Marrow Transplant; 2012 Feb; 18(2):295-301. PubMed ID: 21801704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
